Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline
11:45am, Friday, 25'th Apr 2025
Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.
Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance
10:35am, Friday, 25'th Apr 2025
Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest perfor
2 Pharma Stocks Buzzing in the Options Pits After Earnings
10:32am, Friday, 25'th Apr 2025
Pharmaceutical stocks are making headlines today, after two U.S.-based sector heavyweights stepped into the earnings confessional this morning and last night.
Skechers Posts Weak Revenue, Joins Intel, Gilead Sciences And Other Big Stocks Moving Lower In Friday's Pre-Market Session
08:27am, Friday, 25'th Apr 2025
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Friday.
Gilead Sciences, Inc. (GILD) Q1 2025 Earnings Call Transcript
08:02pm, Thursday, 24'th Apr 2025
Gilead Sciences, Inc. (NASDAQ:GILD ) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Company Participants Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Ch
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say
08:01pm, Thursday, 24'th Apr 2025
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street e
Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates
06:15pm, Thursday, 24'th Apr 2025
Gilead Sciences (GILD) came out with quarterly earnings of $1.81 per share, missing the Zacks Consensus Estimate of $1.82 per share. This compares to loss of $1.32 per share a year ago.
Gilead Dives After Its Bread-And-Butter Drug Misses Sales Forecasts
04:16pm, Thursday, 24'th Apr 2025
Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell in late action.
Gilead reports quarterly profit, revenue flat as cancer sales slow
04:09pm, Thursday, 24'th Apr 2025
Gilead Sciences on Thursday reported slightly higher-than-expected quarterly earnings on flat revenue, as higher sales of drugs for HIV and liver disease along with expense tightening offset lower can
Gilead Sciences Announces First Quarter 2025 Financial Results
04:02pm, Thursday, 24'th Apr 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations. “Gilead had a strong start to the year driven by
Stocks on the Move: Merck, Gilead Sciences, P&G, PG&E Corp, Adobe and the URNM
01:10pm, Thursday, 24'th Apr 2025
The Investment Committee debate how to trade some stocks on the move today.
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
10:10am, Tuesday, 22'nd Apr 2025
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type
08:38am, Monday, 21'st Apr 2025
Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an agg
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy® (sacituz
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
10:40am, Friday, 18'th Apr 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
